Document And Entity Information
Document And Entity Information - shares | 9 Months Ended | |
Sep. 30, 2016 | Nov. 10, 2016 | |
Document Information [Line Items] | ||
Document Type | 10-Q | |
Amendment Flag | false | |
Document Period End Date | Sep. 30, 2016 | |
Document Fiscal Year Focus | 2,016 | |
Document Fiscal Period Focus | Q3 | |
Entity Registrant Name | CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. | |
Entity Central Index Key | 1,187,953 | |
Current Fiscal Year End Date | --12-31 | |
Entity Filer Category | Smaller Reporting Company | |
Trading Symbol | CELZ | |
Entity Common Stock, Shares Outstanding | 102,113,750 |
CONDENSED CONSOLIDATED BALANCE
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) | Sep. 30, 2016 | Dec. 31, 2015 |
CURRENT ASSETS | ||
Cash | $ 33,456 | $ 100 |
Stock subscription receivable | 0 | 49,500 |
Total Current Assets | 33,456 | 49,600 |
OTHER ASSETS | ||
Licenses, net of amortization | 103,281 | 0 |
TOTAL ASSETS | 136,737 | 49,600 |
CURRENT LIABILITIES | ||
Accounts payable | 44,849 | 0 |
Notes payable - related party - current | 100,000 | 0 |
Accrued expenses | 2,822 | 0 |
Management fee payable - related party | 280,000 | 0 |
Notes payable | 15,686 | 0 |
Advances from related party | 2,600 | 100 |
Total Current Liabilities | 445,957 | 100 |
LONG TERM LIABILITIES | ||
Notes payable - related party, net of current portion | 25,000 | 0 |
Accrued expenses, net of current portion | 935 | 0 |
TOTAL LIABILITIES | 471,892 | 100 |
Commitments and contingencies | ||
STOCKHOLDERS’ (DEFICIT) EQUITY | ||
Preferred stock, $0.001 par value, 10,000,000 shares authorized, no shares issued and outstanding | 0 | 0 |
Common stock, $0.001 par value, 600,000,000 shares authorized; 101,313,750 and 32,010,000 shares issued and outstanding, respectively | 101,314 | 32,010 |
Additional paid-in capital | 135,637 | 17,990 |
Accumulated deficit | (572,106) | (500) |
TOTAL STOCKHOLDERS' (DEFICIT) EQUITY | (335,155) | 49,500 |
TOTAL LIABILITIES AND STOCKHOLDERS' (DEFICIT) EQUITY | $ 136,737 | $ 49,600 |
CONDENSED CONSOLIDATED BALANCE3
CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares | Sep. 30, 2016 | Dec. 31, 2015 |
Preferred Stock, Par or Stated Value Per Share | $ 0.001 | $ 0.001 |
Preferred Stock, Shares Authorized | 10,000,000 | 10,000,000 |
Preferred Stock, Shares Issued | 0 | 0 |
Preferred Stock, Shares Outstanding | 0 | 0 |
Common Stock, Par or Stated Value Per Share | $ 0.001 | $ 0.001 |
Common Stock, Shares Authorized | 600,000,000 | 600,000,000 |
Common Stock, Shares, Issued | 101,313,750 | 32,010,000 |
Common Stock, Shares, Outstanding | 101,313,750 | 32,010,000 |
CONDENSED CONSOLIDATED STATEMEN
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) | 3 Months Ended | 9 Months Ended |
Sep. 30, 2016 | Sep. 30, 2016 | |
REVENUES | $ 0 | $ 0 |
OPERATING EXPENSES | ||
Research and development | 45,174 | 67,566 |
General and administrative | 164,732 | 493,484 |
Amortization of patent costs | 2,637 | 6,719 |
TOTAL EXPENSES | 212,543 | 567,769 |
OTHER INCOME/(EXPENSE) | ||
Interest expense | (1,971) | (3,837) |
OPERATING LOSS | (214,514) | (571,606) |
NET LOSS | $ (214,514) | $ (571,606) |
BASIC AND DILUTED LOSS PER SHARE | $ 0 | $ (0.01) |
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING - BASIC AND DILUTED | 100,621,359 | 90,866,349 |
CONDENSED CONSOLIDATED STATEME5
CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS | 9 Months Ended |
Sep. 30, 2016USD ($) | |
CASH FLOWS FROM OPERATING ACTIVITIES: | |
Net loss | $ (571,606) |
Adjustments to reconcile net loss to net cash from operating activities: | |
Stock based compensation | 735 |
Amortization | 6,719 |
Changes in assets and liabilities: | |
Accounts payable | 20,565 |
Accrued expenses | 3,757 |
Management fee payable | 280,000 |
Net cash (used) by operating activities | (259,830) |
CASH FLOWS FROM INVESTING ACTIVITIES: | |
Purchases of licenses | (10,000) |
Net cash (used) by investing activities | (10,000) |
CASH FLOWS FROM FINANCING ACTIVITIES: | |
Cash received from notes payable - related party | 125,000 |
Cash paid on note payable | (4,314) |
Cash received from subscription receivable | 50,000 |
Proceeds from sale of common stock | 130,000 |
Related party advances | 2,500 |
Net cash provided from financing activities | 303,186 |
NET INCREASE IN CASH | 33,356 |
BEGINNING CASH BALANCE | 100 |
ENDING CASH BALANCE | 33,456 |
SUPPLEMENTAL CASH FLOW INFORMATION: | |
Cash payments for interest | 0 |
Cash payments for income taxes | 0 |
NON-CASH FINANCING ACTIVITIES: | |
Purchase of patents by issuance of common stock | 100,000 |
Accounts payable assumed in reverse merger | 24,284 |
Note payable assumed in reverse merger | 20,000 |
Fair value of warrants issued in private placement | $ 8,197 |
ORGANIZATION AND SUMMARY OF SIG
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | 9 Months Ended |
Sep. 30, 2016 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block] | NOTE 1 ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Organization - Company CMT On May 18, 2016, the Company was acquired by a public company, Creative Medical Technology Holdings, Inc. (formerly Jolley Marketing, Inc.) in a “reverse merger” wherein the Company was recapitalized via the common stock of Jolley. Creative Medical Technology Holdings, Inc., formerly Jolley Marketing, Inc. (the “ Public Company CMTH a. CMT advanced $ 25,000 b. The Public Company exchanged 97,000,000 6.466666 c. As part of the acquisition, the Public Company purchased 15,100,000 5,000 d. The shareholders of CMT acquired voting and operating control of the Public Company after the recapitalization; and e. The financial operations of the Public Company, as reported after the merger, are the historical information of CMT. On September 14, 2016, CMT filed a certificate of organization for Amniostem LLC, a Nevada limited liability company and wholly owned subsidiary of CMT. Amniostem, LLC was formed to create and/or license intellectual property in the area of amniotic fluid derived stem cells for therapeutic applications. With this company management intends to address what it believes are unmet medical needs through development and commercialization of amniotic fluid stem cell based technologies. Management intends to seek in licensing opportunities as well as create intellectual property in-house for this newly created entity. - - The accompanying unaudited condensed consolidated financial statements have been prepared without audit. In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position, results of operations and cash flows at September 30, 2016, and for the three and nine month periods then ended have been made. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. The operations for the three and nine-month periods ended September 30, 2016, are not necessarily indicative of the operating results for the full year. The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, which contemplate continuation of the Company as a going concern. However, during the nine months ended September 30, 2016, the Company incurred a net loss of $ 571,606 412,501 The Federal Deposit Insurance Corporation ("FDIC") insures cash deposits in most general bank accounts for up to $ 250,000 Cash Equivalents - The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. - The Company records impairment losses when indicators of impairment are present and undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying amount. Furthermore, the Company will make periodic assessments of technology and clinical testing to determine if it plans to continue to pursue the technology and if the license, patent or other rights have value. The Company will recognize revenue as it is earned as defined by US Generally Accepted Accounting Principles ("GAAP"). During the nine months ended September 30, 2016, there were no sales and revenue was not recognized. For the next several months, until clinical trials have successfully been completed, the Company does not anticipate there will be revenue to report. 1. Erectile Dysfunction Technology based upon the use of stem cells. These costs, which consist primarily of monies paid for clinical trial expenses, materials and supplies and compensation costs amounted to $ 45,174 67,566 2. Infertility Treatment based upon implanting stem cells in the female reproductive system. The costs of acquiring an exclusive license of $ 12,640 The Company accounts for its stock-based compensation in accordance with Accounting Standards Codification ("ASC") 718, Compensation - Stock Compensation. The Company accounts for all stock-based compensation using a fair-value method on the grant date and recognizes the fair value of each award as an expense over the requisite vesting period. The Company follows ASC 505-50, Equity-Based Payments to Non-Employees, for stock options and warrants issued to consultants and other non-employees. In accordance with ASC 505-50, these stock options and warrants issued as compensation for services provided to the Company are accounted for based upon the fair value of the services provided or the estimated fair market value of the option or warrant, whichever can be more clearly determined. The fair value of the equity instrument, which is revalued at each reporting period, is charged directly to compensation expense and additional paid-in capital over the period during which services are rendered. The Company has no provision for income taxes at September 30, 2016, as it has no taxable income and no recognizable tax asset. The Company follows Financial Accounting Standards Board ("FASB") ASC 260 Earnings per Share to account for earnings per share. Basic earnings per share (“EPS”) calculations are determined by dividing net loss by the weighted average number of shares of common stock outstanding during the year. Diluted earnings per share calculations are determined by dividing net income by the weighted average number of common shares and dilutive common share equivalents outstanding. During periods when common stock equivalents, if any, are anti-dilutive they are not considered in the computation. During the three and nine month periods ended September 30, 2016, the Company had 500,000 130,000 The Company has reviewed all recently issued, but not yet adopted, accounting standards in order to determine their effects, if any, on its results of operation, financial position or cash flows. Based on that review, the Company believes that none of these pronouncements will have a significant effect on its financial statements. |
LICENSING AGREEMENTS
LICENSING AGREEMENTS | 9 Months Ended |
Sep. 30, 2016 | |
Licensing Agreements Disclosure [Abstract] | |
Licensing Agreements Disclosure [Text Block] | NOTE 2 LICENSING AGREEMENTS ED Patent The Company acquired a patent from Creative Medical Health, Inc. (“CMH”) a related company on February 2, 2016, in exchange for 64,666,667 100,000 2025 ten 2,521 6,603 Male Infertility License Agreement - The Company has acquired a royalty license from Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (“LABIOMED”) granting the exclusive license to the products and services of a LABIOMED patent. The license was acquired for a cash payment of $ 5,000 50,000 500 0.01 1,800 7,300 The Company is subject to a 6 25 20,000 50,000 Multipotent Amniotic Fetal Stem Cells License Agreement - The Company estimates that the patent expires in February 2026 116 116 |
RELATED PARTY TRANSACTIONS
RELATED PARTY TRANSACTIONS | 9 Months Ended |
Sep. 30, 2016 | |
Related Party Transactions [Abstract] | |
Related Party Transactions Disclosure [Text Block] | NOTE 3 RELATED PARTY TRANSACTIONS The Company has incurred $ 315,000 35,000 1,000,000 280,000 During the nine months ended September 30, 2016, the Company paid $ 3,000 Through September 30, 2016, the Company has entered into three note payable agreements with CMH in which the proceeds were used in operations. The notes payable were dated February 2, 2016 May 1, 2016 May 18, 2016 50,000 50,000 25,000 50,000 April 30, 2017 50,000 July 31, 2017 25,000 May 18, 2018 8 3,757 During the nine month ended September 30, 2016, CMH has advanced the Company $ 2,000 During the nine months ended September 30, 2016, the Company issued 300,000 30,000 30,000 See Note 2 for discussion of an additional related party transaction with CMH. |
STOCK BASED COMPENSATION
STOCK BASED COMPENSATION | 9 Months Ended |
Sep. 30, 2016 | |
Disclosure of Compensation Related Costs, Share-based Payments [Abstract] | |
Shareholders' Equity and Share-based Payments [Text Block] | NOTE 4 STOCK BASED COMPENSATION The Public Company has reserved 2,000,000 In July and September 2016, the Company granted 10 250,000 0.175 The options vest at a rate of 50,000 on each anniversary date of the respective grants. 10,000 Weighted Average Inputs Used Annual dividend yield $ - Expected life (years) 7.40 Risk-free interest rate 1.42 % Expected volatility 87.60 % Common stock price $ 0.10 Since the expected life of the options was greater than the Public Company's historical stock information available, the Public Company determined the expected volatility based on price fluctuations of comparable public companies. Stock based compensation for the three and nine months ended September 30, 2016 was $ 735 735 34,756 2021 |
STOCKHOLDERS' DEFICIT
STOCKHOLDERS' DEFICIT | 9 Months Ended |
Sep. 30, 2016 | |
Stockholders' Equity Note [Abstract] | |
Stockholders' Equity Note Disclosure [Text Block] | NOTE 5 STOCKHOLDERS’ DEFICIT In August 2016, the Company commenced a non-public offering of up to 10,000,000 shares of common stock at $0.10 per share, and at no additional cost, one warrant to purchase another share of common stock at $0.10 per share for each ten shares purchased in the offering. The securities offered have not been and will not be registered under the Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements. From August 6, 2016 to September 30, 2016, the Company sold 1,300,000 130,000 130,000 30,000 8,197 Inputs Used Annual dividend yield $ - Expected life (years) 3.00 Risk-free interest rate 0.86 % Expected volatility 102.59 % Common stock price $ 0.10 See Note 2 for discussion related to the issuance of common stock in connection with licensing agreements. See Note 3 for discussion related to the issuance of common stock to a related party for cash. |
SUBSEQUENT EVENTS
SUBSEQUENT EVENTS | 9 Months Ended |
Sep. 30, 2016 | |
Subsequent Events [Abstract] | |
Subsequent Events [Text Block] | NOTE 6 SUBSEQUENT EVENTS In accordance with ASC 855, management reviewed all material events through November 10, 2016, for these financial statements and there are no material subsequent events to report, except as follows: Subsequent to September 30, 2016, the Company sold 800,000 80,000 80,000 |
ORGANIZATION AND SUMMARY OF S12
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) | 9 Months Ended |
Sep. 30, 2016 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Use of Estimates, Policy [Policy Text Block] | Use of Estimates - |
Basis of Accounting, Policy [Policy Text Block] | Basis of Presentation / Liquidity - The accompanying unaudited condensed consolidated financial statements have been prepared without audit. In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position, results of operations and cash flows at September 30, 2016, and for the three and nine month periods then ended have been made. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. The operations for the three and nine-month periods ended September 30, 2016, are not necessarily indicative of the operating results for the full year. |
Liquidity Policy [Policy Text Block] | Going Concern - The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, which contemplate continuation of the Company as a going concern. However, during the nine months ended September 30, 2016, the Company incurred a net loss of $ 571,606 412,501 |
Concentration Risk, Credit Risk, Policy [Policy Text Block] | Concentration of Credit Risks - The Federal Deposit Insurance Corporation ("FDIC") insures cash deposits in most general bank accounts for up to $ 250,000 |
Cash and Cash Equivalents, Policy [Policy Text Block] | Cash Equivalents - The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. |
Fair Value of Financial Instruments, Policy [Policy Text Block] | Fair Value of Financial Instruments |
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] | Impairment - The Company records impairment losses when indicators of impairment are present and undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying amount. Furthermore, the Company will make periodic assessments of technology and clinical testing to determine if it plans to continue to pursue the technology and if the license, patent or other rights have value. |
Revenue Recognition, Policy [Policy Text Block] | Revenue - The Company will recognize revenue as it is earned as defined by US Generally Accepted Accounting Principles ("GAAP"). During the nine months ended September 30, 2016, there were no sales and revenue was not recognized. For the next several months, until clinical trials have successfully been completed, the Company does not anticipate there will be revenue to report. |
Research and Development Expense, Policy [Policy Text Block] | 1. Erectile Dysfunction Technology based upon the use of stem cells. These costs, which consist primarily of monies paid for clinical trial expenses, materials and supplies and compensation costs amounted to $ 45,174 67,566 2. Infertility Treatment based upon implanting stem cells in the female reproductive system. The costs of acquiring an exclusive license of $ 12,640 |
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block] | Stock-Based Compensation The Company accounts for its stock-based compensation in accordance with Accounting Standards Codification ("ASC") 718, Compensation - Stock Compensation. The Company accounts for all stock-based compensation using a fair-value method on the grant date and recognizes the fair value of each award as an expense over the requisite vesting period. The Company follows ASC 505-50, Equity-Based Payments to Non-Employees, for stock options and warrants issued to consultants and other non-employees. In accordance with ASC 505-50, these stock options and warrants issued as compensation for services provided to the Company are accounted for based upon the fair value of the services provided or the estimated fair market value of the option or warrant, whichever can be more clearly determined. The fair value of the equity instrument, which is revalued at each reporting period, is charged directly to compensation expense and additional paid-in capital over the period during which services are rendered. |
Income Tax, Policy [Policy Text Block] | Income Taxes The Company has no provision for income taxes at September 30, 2016, as it has no taxable income and no recognizable tax asset. |
Earnings Per Share, Policy [Policy Text Block] | Basic and Diluted Loss Per Share The Company follows Financial Accounting Standards Board ("FASB") ASC 260 Earnings per Share to account for earnings per share. Basic earnings per share (“EPS”) calculations are determined by dividing net loss by the weighted average number of shares of common stock outstanding during the year. Diluted earnings per share calculations are determined by dividing net income by the weighted average number of common shares and dilutive common share equivalents outstanding. During periods when common stock equivalents, if any, are anti-dilutive they are not considered in the computation. During the three and nine month periods ended September 30, 2016, the Company had 500,000 130,000 |
New Accounting Pronouncements, Policy [Policy Text Block] | Recent Accounting Pronouncements The Company has reviewed all recently issued, but not yet adopted, accounting standards in order to determine their effects, if any, on its results of operation, financial position or cash flows. Based on that review, the Company believes that none of these pronouncements will have a significant effect on its financial statements. |
STOCK BASED COMPENSATION (Table
STOCK BASED COMPENSATION (Tables) | 9 Months Ended |
Sep. 30, 2016 | |
Employee Stock Option [Member] | |
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] | The fair value of each option award is estimated using the Black-Scholes valuation model. Assumptions used in calculating the fair value at September 30, 2016 were as follows: Weighted Average Inputs Used Annual dividend yield $ - Expected life (years) 7.40 Risk-free interest rate 1.42 % Expected volatility 87.60 % Common stock price $ 0.10 |
STOCKHOLDERS' DEFICIT (Tables)
STOCKHOLDERS' DEFICIT (Tables) | 9 Months Ended |
Sep. 30, 2016 | |
Warrant [Member] | |
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] | Assumptions used in calculating the fair value of the warrants upon issuance were as follows: Inputs Used Annual dividend yield $ - Expected life (years) 3.00 Risk-free interest rate 0.86 % Expected volatility 102.59 % Common stock price $ 0.10 |
ORGANIZATION AND SUMMARY OF S15
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Textual) | 1 Months Ended | 3 Months Ended | 9 Months Ended |
May 18, 2016USD ($)shares | Sep. 30, 2016USD ($)shares | Sep. 30, 2016USD ($)shares | |
Operating Income (Loss) | $ (214,514) | $ (571,606) | |
Working Capital Deficit | 412,501 | 412,501 | |
Cash, FDIC Insured Amount | 250,000 | 250,000 | |
Research and Development Expense | $ 45,174 | $ 67,566 | |
Warrant [Member] | |||
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | shares | 130,000 | ||
Employee Stock Option [Member] | |||
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | shares | 500,000 | ||
Creative Medical Technologies, Inc [Member] | |||
Due to Related Parties | $ 25,000 | ||
Stock Issued During Period, Shares, New Issues | shares | 97,000,000 | ||
Stockholders' Equity Note, Stock Split, Conversion Ratio | 6.466666 | ||
Stock Repurchased and Retired During Period, Shares | shares | 15,100,000 | ||
Stock Repurchased and Retired During Period, Value | $ 5,000 | ||
Erectile Dysfunction Technology [Member] | |||
Research and Development Expense | $ 45,174 | $ 67,566 | |
LABIOMED [Member] | |||
Research and Development Expense | $ 12,640 |
LICENSING AGREEMENTS (Details T
LICENSING AGREEMENTS (Details Textual) - USD ($) | 1 Months Ended | 3 Months Ended | 9 Months Ended | 12 Months Ended |
Feb. 02, 2016 | Sep. 30, 2016 | Sep. 30, 2016 | Dec. 31, 2016 | |
Amortization of Intangible Assets | $ 2,637 | $ 6,719 | ||
Payments to Acquire Intangible Assets | 10,000 | |||
Licensing Agreements [Member] | ||||
Payments to Acquire Intangible Assets | 5,000 | |||
Reimbursement of License fees | $ 1,800 | |||
Shares Issued, Price Per Share | $ 0.01 | $ 0.01 | ||
Royalty Expense | $ 7,300 | |||
Royalty Payment Percentage | 6.00% | |||
Non-Royalty Sublease Income Percentage | 25.00% | |||
Payments for Royalties | $ 20,000 | $ 50,000 | ||
Licensing Agreements [Member] | Restricted Stock [Member] | ||||
Stock Issued During Period, Shares, Purchase of Assets | 50,000 | |||
Stock Issued During Period, Value, Purchase of Assets | $ 500 | |||
Multipotent Amniotic Fetal Stem Cells License Agreement [Member] | Patents [Member] | ||||
Finite-Lived Intangible Asset, Expiration Period | 2,026 | |||
Amortization of Intangible Assets | $ 116 | 116 | ||
Creative Medical Health, Inc [Member] | Patents [Member] | ||||
Stock Issued During Period, Shares, Purchase of Assets | 64,666,667 | |||
Stock Issued During Period, Value, Purchase of Assets | $ 100,000 | |||
Finite-Lived Intangible Asset, Expiration Period | 2,025 | |||
Finite-Lived Intangible Asset, Useful Life | 10 years | |||
Amortization of Intangible Assets | $ 2,521 | $ 6,603 |
RELATED PARTY TRANSACTIONS (Det
RELATED PARTY TRANSACTIONS (Details Textual) - USD ($) | 2 Months Ended | 9 Months Ended | ||
Sep. 30, 2016 | Sep. 30, 2016 | Aug. 31, 2016 | Dec. 31, 2015 | |
Related Party Transaction [Line Items] | ||||
Management Fee Payable | $ 280,000 | $ 280,000 | $ 0 | |
Proceeds from Related Party Debt | 2,500 | |||
Non Public Offering [Member] | ||||
Related Party Transaction [Line Items] | ||||
Maximum Number of Shares to be Issued | 10,000,000 | |||
Stock Issued During Period, Shares, New Issues | 1,300,000 | |||
Proceeds from Issuance or Sale of Equity | $ 130,000 | |||
Creative Medical Health [Member] | ||||
Related Party Transaction [Line Items] | ||||
Management Fee Payable | $ 280,000 | 280,000 | ||
Reimbursement of Management Fees | $ 35,000 | |||
Maximum Number of Shares to be Issued | 1,000,000 | 1,000,000 | ||
Line of Credit Facility, Interest Rate During Period | 8.00% | |||
Interest Payable, Current | $ 3,757 | $ 3,757 | ||
Proceeds from Related Party Debt | $ 2,000 | |||
Stock Issued During Period, Shares, New Issues | 30,000 | |||
Number Of Warrants Issued | $ 30,000 | |||
Professional Fees | 315,000 | |||
Creative Medical Health [Member] | Non Public Offering [Member] | ||||
Related Party Transaction [Line Items] | ||||
Proceeds from Issuance or Sale of Equity | 30,000 | |||
Creative Medical Health [Member] | February Note [Member] | ||||
Related Party Transaction [Line Items] | ||||
Proceeds from Lines of Credit | $ 50,000 | |||
Line of Credit Facility, Initiation Date | Feb. 2, 2016 | |||
Line of Credit Facility, Maximum Borrowing Capacity | 50,000 | $ 50,000 | ||
Line of Credit Facility, Expiration Date | Apr. 30, 2017 | |||
Creative Medical Health [Member] | May Note One [Member] | ||||
Related Party Transaction [Line Items] | ||||
Proceeds from Lines of Credit | $ 50,000 | |||
Line of Credit Facility, Initiation Date | May 1, 2016 | |||
Line of Credit Facility, Maximum Borrowing Capacity | 50,000 | $ 50,000 | ||
Line of Credit Facility, Expiration Date | Jul. 31, 2017 | |||
Creative Medical Health [Member] | May Note Two [Member] | ||||
Related Party Transaction [Line Items] | ||||
Proceeds from Lines of Credit | $ 25,000 | |||
Line of Credit Facility, Initiation Date | May 18, 2016 | |||
Line of Credit Facility, Maximum Borrowing Capacity | $ 25,000 | $ 25,000 | ||
Line of Credit Facility, Expiration Date | May 18, 2018 | |||
Officer [Member] | ||||
Related Party Transaction [Line Items] | ||||
Payments for Other Fees | $ 3,000 |
STOCK BASED COMPENSATION (Detai
STOCK BASED COMPENSATION (Details) - Employee Stock Option [Member] | 9 Months Ended |
Sep. 30, 2016$ / shares | |
Annual dividend yield | 0.00% |
Expected life (years) | 7 years 4 months 24 days |
Risk-free interest rate | 1.42% |
Expected volatility | 87.60% |
Common stock price | $ 0.10 |
STOCK BASED COMPENSATION (Det19
STOCK BASED COMPENSATION (Details Textual) - USD ($) | 3 Months Ended | 9 Months Ended | |
Sep. 30, 2016 | Sep. 30, 2016 | May 18, 2016 | |
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options | $ 34,756 | $ 34,756 | |
Employee Service Share-based Compensation, Nonvested Awards, Expiration Period | 2,021 | ||
General and Administrative Expense [Member] | |||
Allocated Share-based Compensation Expense | $ 735 | $ 735 | |
Restricted Stock [Member] | |||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant | 10,000 | 10,000 | |
Employee Stock Option [Member] | |||
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period | 10 years | ||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | 250,000 | ||
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ 0.175 | ||
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights | The options vest at a rate of 50,000 on each anniversary date of the respective grants. | ||
Stock Incentive Plan 2016 [Member] | |||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized | 2,000,000 |
STOCKHOLDERS' DEFICIT (Details)
STOCKHOLDERS' DEFICIT (Details) - Warrant [Member] | 9 Months Ended |
Sep. 30, 2016$ / shares | |
Annual dividend yield | 0.00% |
Expected life (years) | 3 years |
Risk-free interest rate | 0.86% |
Expected volatility | 102.59% |
Common stock price | $ 0.10 |
STOCKHOLDERS' DEFICIT (Details
STOCKHOLDERS' DEFICIT (Details Textual) - Non Public Offering [Member] - USD ($) | 2 Months Ended | 9 Months Ended | ||
Sep. 30, 2016 | Sep. 30, 2016 | Aug. 31, 2016 | Aug. 06, 2016 | |
Stock Issued During Period, Shares, New Issues | 1,300,000 | |||
Proceeds from Issuance or Sale of Equity | $ 130,000 | |||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 130,000 | |||
Warrants Not Settleable in Cash, Fair Value Disclosure | $ 8,197 | |||
Maximum Number of Shares to be Issued | 10,000,000 | |||
Shares Issued, Price Per Share | $ 0.10 | |||
Class of warrant or Right, Conversion Ratio | one warrant to purchase another share of common stock at $0.10 per share for each ten shares purchased in the offering. | |||
Creative Medical Health [Member] | ||||
Proceeds from Issuance or Sale of Equity | $ 30,000 |
SUBSEQUENT EVENTS (Details Text
SUBSEQUENT EVENTS (Details Textual) - USD ($) | 1 Months Ended | 2 Months Ended | 9 Months Ended | |
Nov. 10, 2016 | Sep. 30, 2016 | Sep. 30, 2016 | Aug. 06, 2016 | |
Subsequent Event [Line Items] | ||||
Proceeds from Issuance of Common Stock | $ 130,000 | |||
Non Public Offering [Member] | ||||
Subsequent Event [Line Items] | ||||
Stock Issued During Period, Shares, New Issues | 1,300,000 | |||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 130,000 | |||
Subsequent Event [Member] | Non Public Offering [Member] | ||||
Subsequent Event [Line Items] | ||||
Stock Issued During Period, Shares, New Issues | 800,000 | |||
Proceeds from Issuance of Common Stock | $ 80,000 | |||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 80,000 |